

Index

1. Introduction.....	1-25
1.1. Thrombogenesis.....	2
1.2. Coagulation cascade.....	3
1.3. Platelet aggregation and mechanism of thrombosis.....	4
1.4. Phases of coagulation cascade and thrombus formation.....	6
1.5. Platelets inhibiting agents.....	8
1.5.1. Cyclooxygenase (COX) inhibitors.....	9
1.5.2. ADP receptor antagonists.....	9
1.5.3. Phosphodiesterase inhibitors.....	10
1.5.4. Glycoprotein IIb/IIIa Inhibitors.....	11
1.6. Anticoagulant agents.....	12
1.6.1. Coumarin derivatives.....	13
1.6.2. Heparin and its derivatives.....	14
1.6.3. Hirudin and its derivatives.....	14
1.6.4. Direct Factor IIa inhibitors.....	15
1.6.5. Direct Factor Xa inhibitors.....	15
1.7. Drawbacks of current drug therapy.....	18
1.8. References.....	20
2. Review of Literature.....	26-44
2.1. Substituted diaryl heterocycles as antiplatelet agents.....	26
2.1.1. Substituted 1,4-diazepine derivatives.....	26
2.1.2. 2-Substituted 4,5-bis(4-methoxyphenyl)pyrimidines.....	27
2.1.3. 2-Guanidino 4,5-bis(4-methoxyphenyl)thiazole.....	28
2.1.4. 2,4,5-Triaryl imidazole derivatives.....	28
2.1.5. 3-Substituted 5,6-bis(4-methoxyphenyl)-1,2,4-triazines.....	29
2.2. Benzoxazinones as antiplatelet agents.....	30
2.3. Vicinal diamides as antithrombotic agents.....	31
2.3.1. Dibenzamidobenzenes.....	31
2.3.2. Anthranilamides.....	33
2.4. References.....	39

3. Aims and objectives.....	45-46
4. Results and discussion.....	47-116
4.1. Chemical studies.....	47
4.1.1. Synthesis of 1,2-diaryl-1,2-ethanedione derivatives	
4.1.1.1. Synthesis of substituted phenylacetic acids (3, 6, 9, 11).....	48
4.1.1.2. Synthesis of substituted diarylethanones (15-32) by Friedel-Craft acylation.....	49
4.1.1.3. Oxidation of substituted diarylethanones to obtain diketo compounds (33-50).....	50
4.1.2. Synthesis of 2-substituted 4,5-diaryl-1 <i>H</i> -imidazole derivatives	
4.1.2.1. Synthesis of 2-(4-chlorophenyl)-4,5-diaryl-1 <i>H</i> -imidazoles (52a-68a)...	50
4.1.2.2. Synthesis of 2-(4-fluorophenyl)-4,5-diaryl-1 <i>H</i> -imidazoles (52b-68b)....	57
4.1.3. Synthesis of 5,6-diaryl- <i>N</i> -(2-morpholinoethyl)-1,2,4-triazin-3-amine derivatives	
4.1.3.1. Synthesis of 5,6-diaryl-3-methylthio-1,2,4-triazines (70-82 and 83-92)..	62
4.1.3.2. Synthesis of <i>N</i> -(2-morpholinoethyl)-1,2,4-triazin-3-amines (94-110)....	73
4.1.4. Synthesis of 2- and 7-substituted 4 <i>H</i> -benzo[<i>d</i>][1,3]oxazin-4-one derivatives	
4.1.4.1. Synthesis of 2-substituted 4 <i>H</i> -benzo[<i>d</i>][1,3]oxazin-4-ones (127a-141a).....	81
4.1.4.2. Synthesis of 7-chloro-2-substituted 4 <i>H</i> -benzo[<i>d</i>][1,3]oxazin-4-ones (127b-141b).....	84
4.1.5. Synthesis of guanido derivatives of anthranilamide	
4.1.5.1. Synthesis of 2-substituted <i>N</i> -amidinobenzamides (143a-157a).....	88
4.1.5.2. Synthesis of 4-chloro-2-substituted <i>N</i> -amidinobenzamides (143b-157b).....	93
4.1.6. Synthesis of 2-substituted 4-chloro- <i>N</i> -pyridin-2-ylbenzamide derivatives (159-173).....	98
4.2. Biological studies.....	105
4.2.1. Biological evaluation of 2-substituted 4,5-diaryl-1 <i>H</i> -imidazoles (52a-68a and 52b-68b)	
4.2.1.1. Human <i>in vitro</i> platelet aggregation assay.....	105
4.2.2. Biological evaluation of 5,6-diaryl- <i>N</i> -(2-morpholinoethyl)-1,2,4-triazin-3-amines (94-110)	

4.2.2.1. Human <i>in vitro</i> platelet aggregation assay.....	107
4.2.2.2. <i>Ex vivo</i> platelet aggregation study.....	107
4.2.2.3. <i>In vivo</i> antithrombotic activity.....	107
4.2.3. Biological evaluation of benzoxazinones and anthranilamides (127b-141b, 143a-157a, 143b-157b, 159-173)	
4.2.3.1. Human <i>in vitro</i> platelet aggregation assay.....	112
4.3. References.....	114
5. Experimental.....	116-204
5.1 Chemical studies	
5.1.1 Synthesis of intermediates for diarylimidazoles and diaryltriazines	
5.1.1.1. Synthesis of substituted phenylacetic acids (3, 6, 9, 11).....	117
5.1.1.2. Synthesis of substituted 1,2-diarylethanones (15-32).....	119
5.1.1.3. Synthesis of substituted diaryl-1,2-diones (33-50).....	125
5.1.2. Synthesis of 4,5-diaryl-1 <i>H</i> -imidazole derivatives	
5.1.2.1. Synthesis of 2-(4-chlorophenyl)-4,5-diaryl-1 <i>H</i> -imidazole derivatives (52a-68a)	132
5.1.2.2. Synthesis of 2-(4-fluorophenyl)-4,5-diaryl-1 <i>H</i> -imidazole derivatives (52b-68b)	140
5.1.3. Synthesis of <i>N</i> -(2-morpholinoethyl)-diaryl-triazin-3-amine derivatives	
5.1.3.1. Synthesis of 3-methylthio-5,6-diaryl-1,2,4-triazines (70-82 and 83-92)...148	
5.1.3.2. Synthesis of <i>N</i> -(2-morpholinoethyl)-diaryl-triazin-3-amines (94-110)...157	
5.1.4. Synthesis of 1,3-benzoxazin-4-one derivatives	
5.1.4.1. Synthesis of substituted 4 <i>H</i> -benzo[<i>d</i>][1,3]oxazin-4-ones (127a-141a)....166	
5.1.4.2. Synthesis of substituted 7-chloro-4 <i>H</i> -benzo[<i>d</i>][1,3]oxazin-4-ones (127b-41b)	171
5.1.5. Synthesis of <i>N</i> -substituted benzamide derivatives	
5.1.5.1. Synthesis of substituted <i>N</i> -amidinobenzamides (143a-157a).....178	
5.1.5.2. Synthesis of substituted 4-chloro- <i>N</i> -amidinobenzamides (143b-157b)...186	
5.1.6. Synthesis of substituted 4-chloro- <i>N</i> -pyridin-2-yl benzamide derivatives	
5.1.6.1. Synthesis of substituted 4-chloro- <i>N</i> -pyridin-2-yl benzamides (159-173)	193

5.2. Biological studies	
5.2.1. <i>In vitro</i> platelet aggregation assay.....	201
5.2.2. <i>Ex vivo</i> antiplatelet study.....	201
5.2.3. <i>In vivo</i> antithrombotic study.....	202
5.3. References.....	204